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Background: Incorrect inhaler technique is a common cause of poor asthma control. This two-phase pragmatic
study evaluated inhaler technique mastery and maintenance of mastery with DuoResp® (budesonide-formoterol
[BF]) Spiromax® compared with Symbicort® (BF) Turbuhaler® in patients with asthma who were receiving inhaled
corticosteroids/long-acting β2-agonists.
Methods: In the initial cross-sectional phase, patients were randomized to a 6-step training protocol with empty
Spiromax and Turbuhaler devices. Patients initially demonstrating ≥1 error with their current device, and then
achieving mastery with both Spiromax and Turbuhaler (absence of healthcare professional [HCP]-observed errors),
were eligible for the longitudinal phase. In the longitudinal phase, patients were randomized to BF Spiromax or BF
Turbuhaler. Co-primary endpoints were the proportions of patients achieving device mastery after three training
steps and maintaining device mastery (defined as the absence of HCP-observed errors after 12 weeks of use).
Secondary endpoints included device preference, handling error frequency, asthma control, and safety. Exploratory
endpoints included assessment of device mastery by an independent external expert reviewing video recordings of
a subset of patients.
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Results: Four hundred ninety-three patients participated in the cross-sectional phase, and 395 patients in the
longitudinal phase. In the cross-sectional phase, more patients achieved device mastery after three training steps with
Spiromax (94%) versus Turbuhaler (87%) (odds ratio [OR] 3.77 [95% confidence interval (CI) 2.05–6.95], p < 0.001).
Longitudinal phase data indicated that the odds of maintaining inhaler mastery at 12 weeks were not statistically
significantly different (OR 1.26 [95% CI 0.80–1.98], p = 0.316). Asthma control improved in both groups with no
significant difference between groups (OR 0.11 [95% CI -0.09–0.30]). An exploratory analysis indicated that the odds of
maintaining independent expert-verified device mastery were significantly higher for patients using Spiromax versus
Turbuhaler (OR 2.11 [95% CI 1.25–3.54]).
Conclusions: In the cross-sectional phase, a significantly greater proportion of patients using Spiromax versus
Turbuhaler achieved device mastery; in the longitudinal phase, the proportion of patients maintaining device mastery
with Spiromax versus Turbuhaler was similar. An exploratory independent expert-verified analysis found Spiromax was
associated with higher levels of device mastery after 12 weeks. Asthma control was improved by treatment with both
BF Spiromax and BF Turbuhaler.
Trial registration: EudraCT 2013-004630-14 (registration date 23 January 2014); NCT02570425.
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Asthma is a worldwide chronic inflammatory disorder of
the airways with major adverse effects on affected indi-
viduals’ quality of life [1]. Despite advances in therapy,
suboptimal asthma control is commonplace and is asso-
ciated with a substantial socioeconomic burden [2–6].
The causes of poor asthma control are multifactorial
and include several patient-related factors. Smoking,
poor treatment adherence, and device handling errors
have all been shown to have a negative impact on
asthma control [7–12].
Therapeutic efficacy of inhalation therapy is
dependent on the drug(s) reaching the targeted areas of
the lower lung [5]. There is a growing body of evidence
suggesting that errors in inhaler technique can reduce
drug delivery to the lungs and produce poor clinical
outcomes [2, 10, 12–16]. Correct inhaler technique
should therefore be considered an essential component
in asthma management [5, 10, 14, 17] and has become
an integral part of the management strategy set out by
the Global Initiative for Asthma (GINA). However, des-
pite the importance of patient training, many health-
care professionals (HCPs) themselves lack proficiency
in correct inhaler use, are not confident in demonstrat-
ing proper inhaler technique and, consequently, pa-
tients are neither taught nor checked in follow-up visits
[18–23]. As a result, poor inhaler technique continues
to represent a barrier to achieving optimal asthma con-
trol among many patients with asthma, a situation that
has not improved over the past 40 years [5, 14, 24–26].
Although the use of all inhalers involves techniques
associated with the preparation of the device, inhalation
and post-inhalation behaviors, some steps associated
with the correct use of different inhalers aredevice-specific [2, 14, 27, 28]. The CRITIKAL study,
which investigated the association between specific in-
haler errors of different devices and asthma outcomes,
enabled the identification of specific inhaler technique
errors that were associated with lack of asthma control
[16]. Other factors shown to be associated with poor
asthma control when using the Turbuhaler® were not
breathing out before an inhalation, not tilting the head
or sealing the lips round the mouthpiece, not using a
fast inhalation and no breath-holding after each inhal-
ation [16].
Because inhaler technique errors have implications for
disease control and HCPs do not always deliver inhaler
technique education [29, 30], it is important that devices
are as intuitive as possible. Additionally, many patients
express preferences for inhaler devices that they are able
to use easily and efficiently [5], but to date, only a few
studies have investigated intuitiveness and the mainten-
ance of device mastery with different inhalers by patients
with asthma [31–33].
Combined use of an inhaled corticosteroid (ICS) and a
long-acting β2–agonist (LABA) is considered to be rec-
ommended for patients with asthma at step 3 or higher
of the GINA guidelines [1]. ICS/LABA fixed-dose
combinations are available in a range of inhaler devices,
including DuoResp® budesonide/formoterol (BF)
Spiromax® and Symbicort® (BF) Turbuhaler. In Europe,
these two products are approved for use in adult
patients with asthma or chronic obstructive pulmonary
disease where an inhaled ICS/LABA is indicated [34].
This Easy Low Instruction Over Time (ELIOT) study
was a pragmatic trial designed to compare the intuitive-
ness of BF Spiromax and a real-life comparator, the BF
Turbuhaler by assessing achievement and maintenance
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with moderate-to-severe asthma.
Methods
The ELIOT study was a pragmatic 12-week, 2-stage,
multicenter, open-label, randomized, parallel-group
study designed to compare the achievement and main-
tenance of inhaler technique in adults with asthma. It
was conducted between May 2014 and March 2015 at
68 centers in the UK. The study was divided into two
parts: a cross-sectional phase at Visit 1, followed by a
12-week longitudinal phase with Visit 2 at the end.
Inclusion and exclusion criteria
Patients aged 18–75 years with a diagnosis of asthma in
accordance with the GINA guidelines [1], as evidenced
by the presence of an Asthma READ Code (UK diagnos-
tic coding system), were eligible to participate in the
study provided they were receiving step 3 or 4 therapy
for asthma as defined by the British Thoracic Society
(BTS) guidelines for persistent asthma [35]. Exclusion
criteria included any previous use of BF Spiromax, use
of the BF Turbuhaler device in the preceding 6 months,
the presence of a significant chronic lower respiratory
tract disease other than asthma, a significant asthmaFig. 1 Study design (a) and procedures (b). aRandomization into cross-ove
inclusion criteria: step 3 or 4 asthma therapy as defined by BTS guidelines
by GINA, and≥ 1 error on current device were included; cVideo review was
providing consent were able to continue in the study. ACQ: Asthma Contro
Asthma; HCP: healthcare professional; PASAPQ: Patient Satisfaction and Preexacerbation, a prescription of oral corticosteroids or
antibiotic treatment within the preceding 2 weeks.
Study design and procedures
As shown in Fig. 1, the study comprised an initial
cross-sectional phase at Visit 1, followed by a 12-week
longitudinal phase with Visit 2 at the end.
Cross-sectional phase
Prior to patient enrollment, HCPs conducting clinics in-
volved in the study were trained to instruct patients on
the correct use of the Spiromax and Turbuhaler devices.
This included emphasizing the prescription dose (two
inhalations, twice per day) and reminding patients to re-
load their device and take the second inhalation. This
prior device training for HCPs was supported by a train-
ing manual and videos showing the proper use of each
device as well as videos highlighting potential errors that
patients could make when using them.
During Visit 1 (Fig. 1a) patients were evaluated on the
handling of their current inhaler device and taught the
proper use of empty Spiromax and Turbuhaler inhalers
by the trained HCPs.
Assessments at this stage (Fig. 1b) included baseline
demographic and clinical characteristics (includingr phase; bRandomization into longitudinal phase; patients meeting the
for persistent asthma, partially or poorly controlled asthma as defined
used only with patients who provided consent; patients not
l Questionnaire; BTS: British Thoracic Society; GINA: Global Initiative for
ference Questionnaire; RCT: randomized control trial
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recording of a patient’s last peripheral blood eosino-
phil level (from medical records, if available), asthma
review (completion of asthma review questionnaire
and asthma control questionnaire [ACQ]), evaluation
of current inhaler technique by HCP assessment and
spirometry. Upon completion of these assessments,
patients were randomized to receive device training
with either empty Spiromax followed by empty
Turbuhaler devices or vice versa. Randomization was
accomplished using interactive response technology
(IRT).
Details of how patients were trained in correct inhaler
technique and how device mastery was determined and
assessed are presented below.Training on inhaler technique and device mastery
After randomization, each patient was trained to use the
empty Spiromax and Turbuhaler devices using a six-step
approach (details provided in Additional file 1: Table
S1), as follows: (1) intuitive use (prior to any training);
(2) after reading patient information leaflet (as supplied
to patients in standard clinical practice); (3) following in-
structional video; (4) following tuition by HCP; (5) fol-
lowing first repeat of tuition by HCP; (6) following
second repeat of tuition by HCP.
After each training step, an assessment of device use
was carried out by HCPs using a predefined list of in-
haler errors (Additional file 1: Table S2) collated from
the best available evidence (developed through steering
committee discussion and consensus). The predefined
list was split into sections relating to dose preparation
and the inhalation maneuver, with separate assessments
being made for inhalations 1 and 2.
Device mastery was defined as the absence of
HCP-observed errors. Once this had been attained or all
six steps had been completed for the first inhaler device,
patients were trained on the second device according to
the randomly assigned order.Recording of patients’ device preferences using the
PASAPQ questionnaire After device training was com-
pleted, patients’ preference for the Spiromax versus the
Turbuhaler was assessed using the Patient Satisfaction
and Preference Questionnaire (PASAPQ). The PASAPQ
is a multi-item measure of respiratory inhalation device
satisfaction and reference, designed and validated in pa-
tients with asthma and chronic obstructive pulmonary
disease [36].
At the end of Visit 1, patients who met the required
criteria for entry into the longitudinal phase of the study
were then randomly assigned to receive treatment with a
BF Spiromax or BF Turbuhaler at an equivalent dose tothe patient’s current ICS and retrained on that device
[35] (Fig. 1).
Patients were eligible to proceed to the longitudinal
phase if they made at least one inhaler technique error
on their existing device (i.e. the one they were using
when they entered the study) and had demonstrated
mastery of both the Spiromax and Turbuhaler devices
during the cross-sectional phase.
Longitudinal phase
In this second phase of the study, patients were ran-
domly assigned to BF Spiromax or BF Turbuhaler for
12 weeks. Randomization to treatment was undertaken
separately from randomization to device training order
during the crossover phase of the study, but using the
same IRT system. Patients were asked to return to the
study center to have their technique checked again at
Visit 2, which took place 12 weeks after Visit 1. In
addition, patients’ asthma control was followed-up by
telephone at Weeks 4, 8 and 12 (no more than 3 days
before Visit 2). During these calls, each patient
self-reported the first 6 items of the ACQ, any adverse
events (AEs) and use of concomitant medications to in-
vestigators who were blinded to the patient’s randomized
treatment assignment.
The maintenance of device mastery was assessed at
Visit 2, 12 weeks after Visit 1. For those patients who
had previously consented to video recording, a video re-
cording of the patient’s handling of the study device at
Visit 2 was also made to enable additional review by an
independent external device expert. Device mastery was
defined as the absence of observed errors after 12 weeks
of device use as assessed by trained HCPs, and by inde-
pendent external experts viewing the video recordings.
Pulmonary function (forced expiratory volume in 1 s
and forced vital capacity) was assessed by spirometry at
Visit 2. Drug safety was monitored by AEs, recorded by
the study investigator or a designee and coded according
to the Medical Dictionary for Regulatory Activities
(MedDRA version 17.0). Investigators were asked to rate
the likelihood of an AE being related to the study medi-
cation as possibly, probably or definitely related. Treat-
ment adherence was assessed by device dose counters
which displayed the number of actuations remaining.
Endpoints
Co-primary
The cross-sectional phase co-primary endpoint was the
proportion of patients in the full-analysis set (FAS; see
below) achieving device mastery after training step 3 (in-
structional video) with Spiromax compared with
Turbuhaler.
The longitudinal phase co-primary endpoint was the
proportion of patients in the full-analysis set maintaining
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Spiromax compared with BF Turbuhaler after 12 weeks
of device use.
Secondary
For the cross-sectional phase, secondary endpoints were:
the proportion of patients achieving device mastery by
steps 1 and 2, the number of steps required to achieve
device mastery, the number of HCP-observed errors,
and the patient device preference (PASAPQ score).
For the longitudinal phase, secondary endpoints were:
the proportion of patients maintaining mastery after
12 weeks of device use when split into dose preparation
and inhalation maneuver steps, total number of observed
errors (assessed by HCP and technology), number of
technology-observed inhalation errors, number of hand-
ling errors, adherence, efficacy (as assessed by ACQ
scores, time to treatment failure [change of treatment or
treatment for exacerbation or infection], exacerbations,
impact of maintaining device mastery on time to treat-
ment failure, use of concomitant medications), and AEs.
Exploratory (longitudinal phase only)
The first exploratory analysis was maintenance of device
mastery at 12 weeks as defined by the absence of exter-
nal expert- (video-)observed errors. Additional explora-
tory analyses included the number and type of HCP-
and external expert-observed errors; aspects of asthma
control (including symptoms and exacerbations) and
current inhaler errors; aspects of asthma control and
current inhaler errors.
Statistical analysis
The FAS comprised patients who completed the cross-
over stage of the study. Patient demographics and base-
line characteristics were summarized using descriptive
statistics. Outcomes for device mastery achievement and
maintenance were compared using parametric or
non-parametric tests, as appropriate. For variables mea-
sured on an interval or ratio scale, a t-test or Mann
Whitney U-test (depending on the distribution of the vari-
able) was used; for categorical variables a Pearson’s
Chi-square (or Fisher’s exact test if sample sizes were too
small) was used. The proportion of patients achieving de-
vice mastery was analyzed using a conditional logistic re-
gression model to calculate an odds ratio (OR), 95%
confidence interval (CI), and p-value to quantify any dif-
ference between devices. The proportion of patients
achieving maintenance of device mastery was analyzed
using logistic regression. Superiority was demonstrated if
the logistic regression model showed that the proportion
of patients maintaining device mastery was significantly
greater (at the 5% level) with one device compared with
the other. The number of steps taken to achieve mastery,counts of errors, and PASAPQ scoring were all analyzed
using paired t-tests or Wilcoxon signed ranks tests, de-
pending on the distributions of the count/score data. The
number and type of HCP- and external expert-
(video-)observed errors were tabulated and Cohen’s Kappa
Coefficient was used to quantify agreement of error
counts between the assessors (HCP and external expert).
HCP-observed errors were analyzed using a negative bino-
mial regression model. The frequencies of errors after
12 weeks were tabulated by device. To assess the mainten-
ance of device mastery according to external expert review
of video recordings, the proportion of patients maintain-
ing mastery of device across treatment groups was com-
pared using a Chi-square test.
Sample size
For the assessment of device mastery, a sample size of
477 patients was needed to achieve 90% power to detect
a difference in proportions of 0.08 when the proportion
of discordant pairs is expected to be 0.282 and the
method of analysis is a McNemar’s test of equality of
paired proportions with a 0.05 two-sided significance
level [37, 38]. For the longitudinal phase, a two-group
Chi-squared test would have 90% power to detect the
difference between maintenance of device mastery of
61.2% for BF Turbuhaler [39] and maintenance of device
mastery of 78.9% for BF Spiromax (OR 0.422) when the
sample size in each group is 139.
Study populations
The FAS was the primary analysis set for all study assess-
ments. For the cross-sectional phase, this included all ran-
domized patients participating in the cross-sectional
phase (cross-sectional phase intent-to-treat [ITT] popula-
tion) who completed assessments on both study devices.
The longitudinal phase FAS included all patients in the
longitudinal phase ITT population who returned for as-
sessment of maintenance of inhaler technique at Visit 2
(week 12), and who had at least 10 weeks of inhaler use to
which they were randomly assigned. The safety population
was specific to the longitudinal phase and included all pa-
tients randomly assigned to treatment and who received
at least one dose of the study drug.
Results
Patients
A total of 540 patients with asthma receiving step 3 or 4
treatment as defined by BTS guidelines were screened,
493 were enrolled and randomized, and 481 were in-
cluded in the cross-sectional phase FAS (Spiromax
followed by Turbuhaler, n = 240; Turbuhaler followed by
Spiromax, n = 241) (Fig. 2). Eleven patients did not have
device assessment because empty Spiromax and Turbu-
haler devices were not available at the site, and one
Fig. 2 Patient disposition in the cross-sectional phase and the longitudinal phase. aEleven patients did not have device assessment because
training devices were not available at the site. Withdrawals during the cross-sectional phase were not captured because of the study design.
bOne patient was eligible for the longitudinal phase and was included in the ITT analysis; however, no device was available at the visit and the
patient withdrew consent before treatment was allocated. cOnly patients who achieved device mastery on both devices could proceed to stage
2. dData were captured retrospectively. eOther reasons for study withdrawal during the longitudinal phase included the following: Visit 2 was not
scheduled and patient inclusion/exclusion criteria were not met. Note: Numbers in parentheses are numbers of patients. Percentages are based
on the number of patients randomly assigned device order in the cross-sectional phase (n = 493). BF: budesonide formoterol; FAS: full analysis
set; ITT: intent-to-treat
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for reasons not recorded.
Prior to enrollment in this study, screened
patients were using breath-actuated inhalers (Easi--
breathe [n = 2], Autohaler [n = 3]), regular metered
dose inhalers (n = 436), and dry powder inhalers
(DPIs) (Diskus (n = 56), Novolizer (n = 1); prior in-
haler use data were unavailable for 42 patients.
Of the 481 patients who completed the cross-sectional
phase, 395 were randomized to the longitudinal phaseand 305 were included in the longitudinal phase FAS
(BF Spiromax, n = 151; BF Turbuhaler, n = 154) (Fig. 2).
Of the latter group, 243 (80%) gave their consent to have
their inhaler technique video-recorded; these patients
were included in the FAS for the exploratory analysis,
which entailed video review of their inhaler technique by
an independent expert.
Patient demographics and baseline characteristics are
summarized in Table 1. The most common comorbidity
among participants in the cross-sectional phase was
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Spiromax followed by Turbuhaler; 24% in those random-
ized to Turbuhaler followed by Spiromax).Device technique evaluations
Cross-sectional phase
The proportion of patients achieving device mastery (ab-
sence of errors) after step 3 (instructional video tuition)
was significantly higher with Spiromax (94.4%) compared
with Turbuhaler (86.9%; p < 0.001) (Table 2). Similarly, the
proportion of patients achieving device mastery using the
Spiromax versus the Turbuhaler in step 1 (intuitive use;
33.3% vs. 11.4%, respectively) and step 2 (after reading the
patient information leaflet; 80.2% vs. 64.0%, respectively)
was significantly higher with Spiromax compared with
Turbuhaler. Furthermore, the number of steps taken to
achieve device mastery and the number of HCP-observed
errors were significantly lower with Spiromax compared
with Turbuhaler (Table 2). Median PASAPQ scores (part 2
of the questionnaire) were statistically significantly higher
for Spiromax versus Turbuhaler (89.8 vs. 85.7; p < 0.001).
Higher levels of dose preparation mastery (97.3% vs.
92.1%; p < 0.001]) and inhalation maneuver mastery
(96.3% vs. 92.5%, respectively; p = 0.007) at the end of step
3 were observed with Spiromax when compared with Tur-
buhaler (Table 2).Longitudinal phase
Table 3 details the assessments of device mastery made
during Visit 2 at the end of the longitudinal phase. The
proportion of patients maintaining HCP-assessed device
mastery over 12 weeks of device use was 58.9% with BF
Spiromax and 53.2% with BF Turbuhaler; these values
were not significantly different (p = 0.316). When theTable 1 Summary of baseline characteristics and demographics
Cross-sectional phase
Empty Spiromax followed
by empty Turbuhaler
(N = 243a)
Empty T
by emp
(N = 242
Age, years, mean (SD) 54.4 (13.8) 53.1 (14
Height, cm, mean (SD) 167.5 (9.1) 169.3 (9
Sex, male, n (%) 91 (37.4) 108 (44.
FEV1, mean (SD) 2.5 (0.8) 2.6 (0.8)
ACQ-7, mean (SD) 1.4 (0.9) 1.6 (0.9)
Eosinophil levels, mean cells/nL (SD) 0.3 (0.3) 0.3 (0.3)
Medications, n (%)
Prior medication 199 (81.9) 195 (80.
Concomitant medication 240 (98.8) 240 (99.
ACQ-7 7-item asthma control questionnaire, BF budesonide formoterol, FEV1 forced
aIntent-to-treat population
bMann-Whitney U Test
cChi-Squared Testerrors that impeded achievement of mastery were split
into those relating to dose preparation and the inhal-
ation maneuver, significantly fewer patients made dose
preparation errors with Spiromax compared with Turbu-
haler (p = 0.007) (Table 3).
In an exploratory investigation, independent external ex-
perts assessed device mastery using video review of
HCP-observed errors for 243 of the 305 (79.7%) patients
participating in the longitudinal phase. Maintenance of mas-
tery according to this analysis was significantly higher with
Spiromax than with Turbuhaler (66.4% vs. 48.4%, respect-
ively; p = 0.005), with patients observed to make less than
half as many errors on average with Spiromax compared
with Turbuhaler (0.47 vs. 1.00 errors per patient; p < 0.001])
(Table 3). The total numbers of HCP- and video-assessed
errors per patient were also significantly lower with BF Spir-
omax compared with BF Turbuhaler (Table 3).
The HCP assessments during Visit 2 of each error
(described in Additional file 1: Table S1) are shown in
Table 4. The most common errors made with both inhalers
were not inhaling fast enough from the start (14–17% of
patients) and incorrectly shaking the inhaler before or after
dose preparation (12–13% of patients). Nineteen patients
(12.3%) using Turbuhaler failed to twist and/or untwist the
base correctly, an action that is not required for Spiromax
dose preparation. Errors specific to preparation of the sec-
ond dose were made by 9–10% of patients using both
inhalers.
Treatment adherence, assessed using device dose
counters, showed no statistically significant difference in
adherence when using the BF Spiromax inhaler versus
BF Turbuhaler. For both regimens, adherence was ≤50%
in 40% of patients. Adherence to treatment was in the
range 51–70% for 13 and 10% of patients with Spiromax
and Turbuhaler, respectively, in the range 71–99% forLongitudinal phase
urbuhaler followed
ty Spiromax
a)
P-value BF Spiromax
(N = 197a)
BF Turbuhaler
(N = 197a)
P-value
.2) 0.309b 53.3 (14.3) 53.1 (14.1) 0.758b
.4) 0.022b 168.1 (8.9) 168.8 (9.5) 0.348b
6) 0.108c 81 (41.1) 82 (41.6) 0.919c
0.238b 2.5 (0.8) 2.6 (0.9) 0.305b
0.043b 1.6 (1.0) 1.6 (0.9) 0.257b
0.279b 0.3 (0.2) 0.3 (0.2) 0.595b
6) 0.711c 179 (90.9) 184 (93.4) 0.350c
2) 0.656c 194 (98.5) 196 (99.5) 0.315c
expiratory volume in 1 second, SD standard deviation
Table 2 Inhaler technique, device mastery and device preference in the cross-sectional phase
Device mastery Empty Spiromax
(N = 481)
Empty Turbuhaler
(N = 481)
Odds ratio (95% CI)a P-value
Step 1 (Intuitive use), nb (%)
[No. of patients participating]
160 (33.3)
[481]
55 (11.4)
[481]
4.89 (3.23–7.40) < 0.001
Step 2 (Patient information leaflet), nb (%)
[No. of patients participating]
386 (80.2)
[321]
308 (64.0)
[426]
2.95 (2.06–4.22) < 0.001
Step 3 (Instructional video), nb (%)
[No. of patients participating]
454 (94.4)
[95]
418 (86.9)
[173]
3.77 (2.05–6.95) < 0.001
Achievement of dose preparation device mastery
(primary endpoint; all patients), n (%)
468 (97.3) 443 (92.1) 4.12 (1.91–8.93) < 0.001
Achievement of inhalation maneuver device mastery (all patients), n (%) 463 (96.3) 445 (92.5) 2.50 (1.28–4.88) 0.007
Number of steps taken to achieve device mastery, median (range) 1 (1–6) 2 (1–5) N/A < 0.001
Number of HCP-observed errors, median (range) 1.91 (0–6) 2.36 (0–6) N/A < 0.001
Patient device preference: PASAPQ score [scale of 1–100], median (range) 89.8c (18.4–100) 85.7c (14.3–100) N/A < 0.001
aOdds ratios are derived from conditional logistic regression of data from paired patients
bNumbers of patients achieving mastery at each stage are cumulative (i.e. patients achieving mastery at previous step(s) are included). Patients demonstrating
mastery did not proceed to the next step; they were either proceeded to the second inhaler or finished the study (if they were using the second inhaler)
cn = 477 for each. CI confidence interval, HCP, healthcare professional, N/A not applicable, PASAPQ Patient Satisfaction and Preference Questionnaire
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just 1 and 4% of patients with these respective devices.
Taking adherence into account, the average ICS daily
dose in both groups was lower than the 800 μg/day in-
clusion criterion: 765 μg/day among BF Spiromax and
740 μg/day among BF Turbuhaler users who returned
all of their devices (n = 227). All but nine patients
returned at least one partially or completely full device.
Efficacy and safety
Asthma control improved after 12 weeks of treatment in
both treatment groups: mean changes in the 7-item
ACQ from baseline to week 12 showed no statistically
significant differences between BF Spiromax (− 0.20) and
BF Turbuhaler (− 0.31) (OR [95% CI]: 0.11 [− 0.09–0.30];Table 3 Maintenance of device mastery and inhalation errors after 1
Outcome
HCP-observed errors
Patients without errors (inhalations 1 & 2) (co-primary endpoint), n (%)
Patients without errors related to dose preparation (inhalation 1), n (%)
Patients without errors related to the inhalation maneuver (inhalation 1), n
Number of HCP-observed errors per patient, mean (SD)
HCP-observed errors reassessed by video expert review (exploratory analysis)
nb
Total number of errors observed by video expert
Patients without errors (inhalations 1 & 2), n (%)
Number of video expert assessed errors per patient, mean (SD)
BF budesonide formoterol, CI confidence interval, HCP healthcare professional, SD s
aDerived from Chi-squared test
bNote: Six patients for whom errors were reassessed by independent video review
in the table
cEstimated from logistic regression models
dEstimated from negative binomial regression modelp = 0.278). Blood eosinophil levels were generally not
correlated with baseline ACQ, asthma control, or inhaler
errors (Spearman’s correlation < 0.3).
Over 12 weeks of treatment, 57% of patients using BF
Spiromax and 60% of patients using BF Turbuhaler ex-
perienced at least one AE (Table 5), most of which were
mild or moderate in severity and deemed unrelated to
treatment. The incidences of events considered by inves-
tigators to be possibly, probably or definitely related to
study medication were 6.1% in the BF Spiromax group
and 9.1% in the BF Turbuhaler group. Serious AEs were
reported in 12 patients (4 on BF Spiromax and 8 on BF
Turbuhaler) (Table 5; Additional file 1: Table S3), but
these were generally deemed to be unrelated to study
treatment. One serious AE (worsening of asthma, in a2 weeks in the longitudinal phase
BF Spiromax
(N = 151)
BF Turbuhaler
(N = 154)
Odds ratio (95% CI) P-valuea
89 (58.9) 82 (53.2) 1.26 (0.80–1.98)c 0.316
128 (84.8) 111 (72.1) 2.16 (1.22–3.80)c 0.007
(%) 117 (77.5) 116 (75.3) 1.13 (0.66–1.92)c 0.657
0.50 (0.67) 0.81 (1.10) 0.61 (0.44–0.84)d 0.003
119 124 – –
56 124 – –
79 (66.4) 60 (48.4) 2.11 (1.25–3.54)c 0.005
0.47 (0.78) 1.00 (1.26) 0.47 (0.34–0.64)d < 0.001
tandard deviation
were not included in the full analysis set; data for these patients are not shown
Table 4 Frequency of HCP-observed errors after 12 weeks of device use in the longitudinal phase
BF Spiromax
(N = 151)
BF Turbuhaler
(N = 154)
Number of patients with at least one error, n (%) 62 (41.1%) 72 (46.8%)
Total errors, n 75a 125a
Does not hold the inhaler with the semi-transparent mouthpiece cover at the bottom 0 N/A
Spiromax: Does not open cap
Turbuhaler: Does not remove cap
0 0
Dose preparation: A click is not heard when the cap is opened 0 N/A
Dose preparation: not twisting the base as far as possible, until it clicks and not turning
it back to the original position
N/A 19 (12.3%)
Spiromax: Inhaler is not held upright when a dose is prepared (±90° is acceptable)
Turbuhaler: Inhaler is not held upright (mouthpiece skywards ±45°) when a dose is prepared
throughout dose preparation
4 (2.6%) 8 (5.2%)
Turbuhaler: Device not held upright (upright means mouthpiece pointed skywards ±45°)
after the base is twisted until inhalation
N/A 8 (5.2%)
Vigorous shaking before or after dose preparation 19 (12.6%) 18 (11.7%)
Exhales into the inhaler before taking dose 8 (5.3%) 13 (8.4%)
Fails to put in mouth and seal lips around mouthpiece 1 (0.7%) 1 (0.6%)
Spiromax: Finger (or face) placed over the air inlet during an inhalation (at front above the mouthpiece)
Turbuhaler: Fingers or mouth placed around air inlets (positioned around the base and above the mouthpiece)
2 (1.3%) 10 (6.5%)
Inhalation is not as fast as possible (from the start) 25 (16.6%) 22 (14.3%)
Errors involving a second dose error, n
Spiromax: Does not close cap after the inhalation and load a new dose; a click is not heard when the
cap is opened
Turbuhaler: Does not load a new dose as described; dose preparation: not twisting the base as
far as possible, until it clicks and not turning it back to the original position
14 (9.3%) 15 (9.7%)
Spiromax: Does not close the inhaler after taking the second dose
Turbuhaler: Does not place the cap back on the inhaler after taking the second dose
1 (0.7%) 7 (4.5%)
Does not know how to read out the dose counter after asking the patient to check the number of doses left 0 4 (2.6%)
BF budesonide formoterol, HCP healthcare professional, N/A not applicable
aCohen’s Kappa Coefficient (measure the inter-rater (HCP and external) agreement of error) = − 0.606
Table 5 AEs occurring in ≥ 2% of patients
BF Spiromax
(N = 197)
BF Turbuhaler
(N = 197)
Patients with at least 1 AE, n (%) 113 (57.4) 119 (60.4)
Infections and infestations
Lower respiratory tract infection 17 (8.6) 31 (15.7)
Urinary tract infection 5 (2.5) 2 (1.0)
Nervous system disorders
Headache 5 (2.5) 2 (1.0)
Respiratory, thoracic, and mediastinal disorders
Asthma (worsening of asthma or asthma attack) 8 (4.1) 9 (4.6)
Cough 11 (5.6) 12 (6.1)
Dyspnea 5 (2.5) 5 (2.5)
Wheezing 4 (2.0) 3 (1.5)
Number of patients with at least 1 serious AE, n (%) 4 (2.0) 8 (4.1)
AE adverse event, BF budesonide formoterol
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the investigator to be related to the study treatment.
Withdrawals due to AEs were similar in the two study
groups; the AEs most frequently causing withdrawal
were cough, dyspnea, oral candidiasis, and worsening of
asthma or asthma exacerbation.
Discussion
In this two-part pragmatic study, Spiromax was associated
with higher levels of device mastery compared with
Turbuhaler after training in the initial crossover phase.
During this phase, patients were significantly less likely to
make an HCP-observed error with the empty Spiromax
device compared with the empty Turbuhaler device in in-
tuitive use, after reading the patient information leaflet,
and after viewing an instructional video. In addition, pa-
tients using the empty Spiromax achieved device mastery
in fewer steps and made fewer errors overall.
In the longitudinal phase of the study, the proportion
of patients maintaining device mastery (absence of
HCP-observed errors upon assessment after 12 weeks of
device use) was numerically higher with BF Spiromax
than with BF Turbuhaler, but not statistically signifi-
cantly so. However, in the exploratory analysis wherein
an independent external expert viewed video recordings
of participants’ inhaler usage, higher levels of mastery
than were reported by the HCPs were reported, suggest-
ing that HCPs may have had a tendency to over-estimate
the number of errors.
The findings of the cross-sectional phase support the
hypothesis that patients may find it easier to attain mas-
tery of Spiromax compared with Turbuhaler. Fewer er-
rors were observed with both devices when patients
received tuition by reading the patient information leaf-
let and watching the instructional video (step 3; verbal
instruction and demonstration given) than after reading
the leaflet alone (step 2; no verbal instructions given).
Device mastery at step 2 was achieved in a significantly
greater proportion of patients using Spiromax versus
Turbuhaler, but rates of achievement of device mastery
were markedly increased following viewing of the in-
structional video at step 3.
In a ‘real-world’ setting, many patients may not have
access to video instructions, or they may be of variable
quality. In contrast, all patients should receive the pa-
tient leaflet, so maximizing patient mastery of inhaler
technique using this resource is an important objective.
The outcomes of this study are in agreement with previ-
ously published findings that passive instructions alone
(such as reading the patient information leaflet) are not
as effective as verbal instructions or demonstration (such
as watching an instructional video) in teaching patients
correct inhaler technique, specifically in patients using
inhalers for the first time [40–43]. Other instructionaltools for the training of correct inhaler technique should
be considered, including verbal instructions and multi-
media educational materials (e.g. a link to a
website-based instructional video could be included in
the patient information leaflet). Demonstrations and
practice sessions should also be considered in clinical
practice to maximize the number of patients with cor-
rect inhaler technique [5, 31, 32, 41, 44–47]. Overall, in
order to improve device mastery, HCPs should consider
a range of factors including the inhaler type, the patient,
the educator/teacher, and the method of teaching [48].
Possible reasons why the longitudinal phase mastery
results (based on HCP-observed errors) did not demon-
strate a significant difference between the two devices
include the fact that many longitudinal phase partici-
pants had previous experience of using the Turbuhaler
(albeit more than 6 months prior to the study), whereas
none had used the Spiromax. Cross-sectional studies
[16, 24, 25] have reported a much higher frequency of
errors with Turbuhaler than that observed in this study.
Another possible explanation is the frequent telephone
follow-up of patients, a situation rather different from
normal clinical practice, which could have had an impact
on the proportion of patients maintaining correct tech-
nique. Maintenance of correct device technique may be
influenced by patient motivation. Previous studies, in
which patients received intensive inhaler technique edu-
cation in a community pharmacy setting, and had their
technique checked 1 month later back at the pharmacy,
showed correct technique in about 45 to 60% of patients
at this time [31, 45].
It could also be argued that HCP assessment is prone to
human observational errors. The discrepancy between
HCP-reported error rates and those obtained through in-
dependent expert assessment of video-recorded use that
was observed in our exploratory analysis suggests that
HCPs may be conservative with patient assessments or
lack experience and require training in assessment them-
selves, potentially resulting in over-estimation of error
rates. In real-life clinical settings, it could be beneficial for
external experts to review each patient’s inhaler technique
with HCPs. The implementation of such assessment in
busy clinics would be a challenge, and if this is not feas-
ible, HCPs should ensure that they maintain their own in-
haler technique mastery and periodically review each
other’s technique. In the future, smartphone apps (includ-
ing video recording of inhalation technique at home or
augmented reality facial mapping) could become an op-
tion, as well as new technologies incorporating electronic
sensors to inhalers. This study therefore highlights the po-
tential for technology-assisted methods to enhance teach-
ing and assessment of inhaler technique. Our findings also
suggest that HCPs should receive training on inhaler tech-
nique and its evaluation, to ensure that they monitor their
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of an inhalation device expert.
Another important aspect of this study was the ana-
lysis of specific aspects of device mastery such as dose
preparation. Spiromax was associated with significantly
higher levels of dose preparation mastery in the
cross-sectional phase compared with Turbuhaler and
significantly fewer HCP-observed errors after the longi-
tudinal phase. Errors in dose preparation can signifi-
cantly impair effective delivery of drug to the lungs,
leading to a risk of inadequate treatment dosing (or even
no drug dose) [5, 8, 14, 46]. Previous studies have re-
ported that dose preparation errors are device-specific
whereas errors in inhalation maneuvers are usually ob-
served across different devices of a particular type (in
this study, both devices were DPIs) [24, 25, 49]. Studies
in which dose preparation errors have been specifically
examined report error rates of between 24 and 49% with
Turbuhaler in patients who use this device for their
regular medication [16, 49] and in 16.7% of people who
are using Turbuhaler for the first time and have read the
patient leaflet [43]. The findings of the latter study are
consistent with the outcomes from our research, in that
both studies found that (1) Spiromax was associated
with a lower rate of dose preparation errors compared
with Turbuhaler, and (2) maximal device mastery is
achieved after HCP education and demonstration [43].
Research shows that when patients learn correct inhaler
technique and adhere to treatment for 7 days, they are
more likely to maintain device mastery over time [50].
It has recently been shown that not using a fast inhal-
ation when using dry powder inhalers is one of the prin-
cipal errors related to a greater incidence of poor
asthma control [16]. Dose emission from a DPI is af-
fected by inhalation flow, but the extent of variability
differs between devices, so that it may be beneficial to
use an inhaler with low variability [51].
Participants were instructed to take two inhalations
twice daily, and the preparation of the second dose
formed an important part of the device mastery assess-
ment. Many of the inhalation 2 errors were due to pa-
tients making two inhalations from the first dose that
was prepared, instead of preparing a second dose. They
made a second inhalation either without closing and
opening the cap of the Spiromax inhaler or without ro-
tating the base of the Turbuhaler. Patients were ob-
served to make this type of error with both Spiromax
and Turbuhaler with a similar frequency, suggesting that
they may have misinterpreted the dosing instructions or
had never properly been instructed. Further studies are
therefore required to investigate if this is a problem that
needs to be addressed. The role of HCPs in ensuring
that patients are fully aware of all steps required, includ-
ing those that apply when taking a second dose ifapplicable, and directing patients to suitable training
material, must therefore be emphasized.
Patients are more likely to prefer a device that they con-
sider easy to use and that they can use correctly, and pa-
tient satisfaction with an inhaler is correlated with clinical
outcomes [5, 10, 17, 44, 48, 52]. Hence, selecting the cor-
rect inhaler device by matching the patient with the in-
haler that they prefer and find more intuitive to use could
potentially lead to improved adherence, better clinical out-
comes and reduced costs for care [5, 13, 28, 48, 53].
Although the between-group difference was small,
patient-reported PASAPQ scores for Spiromax and
Turbuhaler were significantly in favor of the empty
Spiromax (PASAPQ score 89.8 vs. 85.7 for Turbuhaler;
p < 0.001), indicating higher device preference with
Spiromax. Similar findings were reported in two recent
studies [43, 54]. One of these was a clinical study com-
paring BF Spiromax with BF Turbuhaler in patients with
asthma; PASAPQ scores showed that patients preferred
the Spiromax device for its performance and that they
were more willing to continue therapy with Spiromax
beyond the 12-week study period [54]. In the other
study, device preference questionnaire results from
inhaler-naïve Finnish volunteers showed that the major-
ity of participants found Spiromax easier to use than
Easyhaler or Turbuhaler and, if they were prescribed an
inhaler, they would prefer Spiromax [43]. In our study,
device preference was only assessed in the
cross-sectional phase. It would be relevant to know
whether device preference or satisfaction was maintained
after 12 weeks of using the active inhaler (i.e. by repeat-
ing the PASAPQ at the end of the study and comparing
the outcomes with the cross-sectional phase).
One strength of the current study is the assessment of
the maintenance of device mastery, which has been ad-
dressed in very few other pragmatic studies in asthma [31,
32, 45]. This begins to address a gap in the literature and
provides a preliminary insight into the possible impact of
inhaler technique and mastery on disease control. For a
formal assessment, adjustment for confounding factors
such as adherence will be required. Our study suggests
that maintaining good inhaler technique could provide
benefits to patients receiving high-dose ICS medication, as
the daily dose of beclomethasone dipropionate-equivalent
ICS in patients enrolled in this study was 800–2000 μg
(fixed or free combinations with LABA). Dose modifica-
tion and alternative choices for improving asthma con-
trol are generally limited in these patients. Another
strength of this pragmatic study was the assessment
of patients in real-life scenarios. In general, random-
ized clinical trials (RCTs) provide evidence from nar-
rowly defined patient groups representing subsets of
the real-life patient population; co-morbidities and
lifestyle factors are not usually captured. Findings
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a broader asthma population and can be combined
with findings from conventional RCTs to provide a
comprehensive picture of treatment efficacy and out-
comes [55]. Among the limitations of this study are
the open-label design, potential confounding associ-
ated with 4-weekly follow-up acting as a reminder to
patients, and the subjective nature of some assess-
ments such as HCP observations making it inherently
prone to a degree of bias and personal judgment. The
4-weekly follow-up calls, in particular, may have had
a positive influence on patients’ device mastery, as
previous research has shown that regular follow-up of
patients affects device mastery over time [31, 50]. A regi-
men requiring two doses to be taken twice daily also rep-
resents a dosing frequency greater than that typically
found in the clinic, where patients more usually adminis-
ter one dose, twice daily. In addition, the findings are not
necessarily applicable to mild asthma which was outside
of the scope of this study.
Conclusions
In the cross-sectional phase of this study, Spiromax was as-
sociated with higher levels of device mastery compared
with Turbuhaler in adult patients with moderate-to-severe
asthma. No significant overall difference between the de-
vices was observed by HCP assessment of inhaler technique
in the longitudinal phase, though Spiromax users were ob-
served to make fewer dose preparation errors than those
using Turbuhaler. An exploratory investigation involving
external expert assessment of inhalation technique by video
reported higher levels of maintenance of device mastery
during the longitudinal phase with Spiromax versus Turbu-
haler. Improvements in asthma control, similar with both
devices, were observed over 12 weeks of BF treatment, des-
pite low adherence levels in both study groups. In accord-
ance with previous studies, device preference was higher
with Spiromax than with Turbuhaler. This study supports
the use of active (e.g. verbal) training to minimize the likeli-
hood of inhalation errors. Our findings also highlight the
possible value of independent assessment using video to as-
sist HCPs in evaluating patients’ device mastery.
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